Centessa Pharmaceuticals CNTA Stock
Centessa Pharmaceuticals Price Chart
Centessa Pharmaceuticals CNTA Financial and Trading Overview
| Centessa Pharmaceuticals stock price | 40.5 USD |
| Previous Close | 0 USD |
| Open | 40.09 USD |
| Bid | 29.07 USD x 100 |
| Ask | 51.57 USD x 100 |
| Day's Range | 40 - 40.56 USD |
| 52 Week Range | 13.22 - 40.56 USD |
| Volume | 11.27M USD |
| Avg. Volume | 1.9M USD |
| Market Cap | 6.27B USD |
| Beta (5Y Monthly) | 1.121 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.78 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.25 USD |
CNTA Valuation Measures
| Enterprise Value | 6.11B USD |
| Trailing P/E | N/A |
| Forward P/E | -22.75281 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | |
| Price/Book (mrq) | 12.857142 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -23.829 |
Trading Information
Centessa Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.121 |
| 52-Week Change | 187.84% |
| S&P500 52-Week Change | 20.84% |
| 52 Week High | 40.56 USD |
| 52 Week Low | 13.22 USD |
| 50-Day Moving Average | 39.77 USD |
| 200-Day Moving Average | 29.97 USD |
CNTA Share Statistics
| Avg. Volume (3 month) | 1.9M USD |
| Avg. Daily Volume (10-Days) | 2.87M USD |
| Shares Outstanding | 154.73M |
| Float | 92.48M |
| Short Ratio | 1.35 |
| % Held by Insiders | 0.67% |
| % Held by Institutions | 96.93% |
| Shares Short | 1.61M |
| Short % of Float | 1.22% |
| Short % of Shares Outstanding | 1.04% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | NaN |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.43% |
| Return on Equity (ttm) | -57.38% |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 0 USD |
| EBITDA | -256344992 USD |
| Net Income Avi to Common (ttm) | -250638000 USD |
| Diluted EPS (ttm) | -1.78 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 276.59M USD |
| Total Cash Per Share (mrq) | 1.79 USD |
| Total Debt (mrq) | 118.56M USD |
| Total Debt/Equity (mrq) | 24.33 USD |
| Current Ratio (mrq) | 9.534 |
| Book Value Per Share (mrq) | 3.15 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -208795008 USD |
| Levered Free Cash Flow (ttm) | -128715624 USD |
Profile of Centessa Pharmaceuticals
| Country | United States |
| State | N/A |
| City | Altrincham |
| Address | 1 Ashley Road |
| ZIP | WA14 2DT |
| Phone | N/A |
| Website | https://centessa.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 129 |
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Q&A For Centessa Pharmaceuticals Stock
What is a current CNTA stock price?
Centessa Pharmaceuticals CNTA stock price today per share is 40.5 USD.
How to purchase Centessa Pharmaceuticals stock?
You can buy CNTA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Centessa Pharmaceuticals?
The stock symbol or ticker of Centessa Pharmaceuticals is CNTA.
Which industry does the Centessa Pharmaceuticals company belong to?
The Centessa Pharmaceuticals industry is Biotechnology.
How many shares does Centessa Pharmaceuticals have in circulation?
The max supply of Centessa Pharmaceuticals shares is 154.73M.
What is Centessa Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Centessa Pharmaceuticals PE Ratio is now.
What was Centessa Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Centessa Pharmaceuticals EPS is -1.78 USD over the trailing 12 months.
Which sector does the Centessa Pharmaceuticals company belong to?
The Centessa Pharmaceuticals sector is Healthcare.
Centessa Pharmaceuticals CNTA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26009.36 USD — |
-0.99
|
3.2B USD — | 25968.44 USD — | 26165.37 USD — | — - | 3.2B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12770.82 USD — |
-0.98
|
— — | 12749.29 USD — | 12846.72 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6534.83 USD — |
-0.41
|
— — | 6521.66 USD — | 6597.56 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1254.87 USD — |
+0.23
|
— — | 1251.58 USD — | 1265.64 USD — | — - | — — |
- {{ link.label }} {{link}}